Table 1.
Clinicopathological associations of MEDAG expression in breast cancer.
| Variables | Negative, n = 36 | Positive, n = 65 | P value* |
|---|---|---|---|
| Age at diagnosis, years | 0.775 | ||
| <50 | 15 (41.7) | 29 (44.6) | |
| ≥50 | 21 (58.3) | 36 (55.4) | |
| Menopausal status | 0.603 | ||
| Premenopausal | 18 (50.0) | 29 (44.6) | |
| Postmenopausal | 18 (50.0) | 36 (55.4) | |
| Tumor size(mm) | 0.987 | ||
| ≤20 | 16 (44.4) | 29 (44.6) | |
| >20 | 20 (55.6) | 36 (55.4) | |
| Lymph node metastasis | 0.042 | ||
| Negative | 22 (61.1) | 26 (40.0) | |
| Positive | 14 (38.9) | 39 (60.0) | |
| Vascular invasion | 0.033 | ||
| Negative | 36 (100.0) | 55 (84.6) | |
| Positive | 0 (0.0) | 10 (15.4) | |
| ER | 0.292 | ||
| Negative | 20 (55.6) | 29 (44.6) | |
| Positive | 16 (44.4) | 36 (55.4) | |
| PR | 0.307 | ||
| Negative | 21 (58.3) | 34 (52.3) | |
| Positive | 15 (41.7) | 31 (47.7) | |
| HER2 | 0.096 | ||
| Negative | 26 (72.2) | 36 (55.4) | |
| Positive | 10 (27.8) | 29 (44.6) | |
| Ki67 | 0.294 | ||
| <4% | 13 (36.1) | 17 (26.2) | |
| ≥14% | 23 (63.9) | 48 (73.8) | |
| Surgery | 0.903 | ||
| Mastectomy | 34 (94.4) | 61 (93.8) | |
| BCS | 2 (5.6) | 4 (6.2) | |
| Chemotherapy | 0.461 | ||
| None | 7 (19.4) | 9 (13.8) | |
| Yes | 29 (80.6) | 56 (86.2) |
*P values calculated by Pearson Chi squared testing; Bold if statistically significant, P < 0.05.
ER estrogen receptor, PR progesterone receptor, HER2 human epithelial growth factor receptor-2, BCS breast-conserving surgery.